...members of the special committee are company founder Herbert Boyer, San Diego Gas & Electric Co Chief Executive Debra Reed and former GlaxoSmithKline Plc CEO Charles Sanders. "The special committee intends to proceed in a timely manner to review the Roche proposal,...

...largest commitment to stem cell research by a pharmaceutical company was announced yesterday. GlaxoSmithKline of the UK said it would invest at least $25m (€15.8m. £12.5m) over five years on a collaborative agreement with the Harvard Stem Cell Institute, "leading...

...will invest at least $25m over five years on a collaborative agreement with the Harvard Stem Cell Institute, ‘leading to the development of new medicines’ NOTE: My spam filter automatically deletes any TrackBacks that do not actually link and refer to this...

...largest commitment to stem cell research by a pharmaceutical company was announced on Thursday. GlaxoSmithKline of the UK said it would invest at least $25m (€15.8m. £12.5m) over five years on a collaborative agreement with the Harvard Stem Cell Institute,...

...the successful achievement of proof-of-concept in this Phase 2 clinical study, we earned a milestone payment of $10 million from GlaxoSmithKline (GSK). We recently reported clinical results from our Phase 1 study in the LAMA program with our lead investigational...

...the developing world now get HIV drugs -- about 70 percent of those who need them, according to the United Nations. Makers include GlaxoSmithKline <GSK.L>, which helped pay for the Lancet study, Gilead Sciences Inc <GILD.O>, Roche <ROG.VX>, Pfizer <PFE.N>,...

...on the U.S. market, and one FP expert AAFP News Now consulted says he harbors mixed feelings about that prospect. Manufactured by GlaxoSmithKline, diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine, or DTaP-IPV,...

...the pharma company GlaxoSmithKline (GSK) announced a five-year, $25-million-plus collaborative agreement with the Harvard Stem Cell Institute to develop new methods for screening drugs with stem cells. "GSK believes stem cell science has great potential to...

...include running diagnostic sleep labs, bills itself as "America's Sleep Company." As we pointed out last week in a post on a GlaxoSmithKline plc's $2.7 billion sleeping pill deal, the treatment of sleep disorders is a huge business in our hectic world. Whether...

...health industry was challenging, but the business environment had not informed its decision to sell drugs in joint venture with GlaxoSmithKline (GSK). "The SA environment has a lot of challenges, and capping prices don't make sense," said Stephen Saad, CEO...